NCT05411809View on ClinicalTrials.gov

The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

June 15, 2022

Primary Completion Date

June 15, 2024

Study Completion Date

May 15, 2027

Conditions
Stereotactic Body Radiation Therapy
Interventions
DRUG

drug adjuvant therapy

The adjuvant treatment regimens depend on the judgment of oncology physicians according to pathological type, molecular characteristics and other details of the tumor.

Trial Locations (1)

100191

Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist., Beijing

All Listed Sponsors
lead

Peking University Third Hospital

OTHER

NCT05411809 - The ctDNA for Evaluating Whether to Use Adjuvant Therapy After SBRT in Patients With Early Lung Cancer | Biotech Hunter | Biotech Hunter